直腸癌新輔助治療對患者生活質量的影響_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 王磊 ^1,2 , 秦啟元 ¹ , 潘子奇 ³

1. ;
2. ;
3. ;

Corresponding?author：

王磊, Email: wangl9@mail.sysu.edu.cn

Keywords：

DOI：

10.7507/1007-9424.201810041

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王磊, 秦啟元, 潘子奇. 直腸癌新輔助治療對患者生活質量的影響. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(11): 1290-1293. doi: 10.7507/1007-9424.201810041 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, Sep 12.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	王磊, 劉志華, 汪建平. 我國結直腸癌的診療現狀. 中華實驗外科雜志, 2015, 32(4): 677-679.
4.	Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
5.	van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol, 2011, 12(6): 575-582.
6.	Qin Q, Wang L. Neoadjuvant therapy and subsequent treatment in rectal cancer: balance between oncological and functional outcomes. J Anus Rectum Colon, 2018, 2(2): 47-58.
7.	Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol, 2005, 23(24): 5644-5650.
8.	Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years. J Clin Oncol, 2012, 30(16): 1926-1933.
9.	Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol, 2012, 30(31): 3827-3833.
10.	Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg, 2006, 93(10): 1215-1223.
11.	Ansari N, Solomon MJ, Fisher RJ, et al. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). Ann Surg, 2017, 265(5): 882-888.
12.	Bujko K, Nowacki MP, Kepka L, et al. Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation. Colorectal Dis, 2005, 7(4): 410-416.
13.	Ma B, Gao P, Song Y, et al. Short-course radiotherapy in neoadjuvant treatment for rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer, 2018 Aug 11. pii: S1533-0028(18)30295-0.
14.	Kripp M, Wieneke J, Kienle P, et al. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer-impact on long-term quality of life. Eur J Surg Oncol, 2012, 38(6): 472-477.
15.	Sclafani F, Peckitt C, Cunningham D, et al. Short- and long-term quality of life and bowel function in patients with mri-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 expert-c trial. Int J Radiat Oncol Biol Phys, 2015, 93(2): 303-312.
16.	Bregendahl S, Emmertsen KJ, Lous J, et al. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis, 2013, 15(9): 1130-1139.
17.	Bryant C L, Lunniss P J, Knowles C H, et al. Anterior resection syndrome. Lancet Oncol, 2012, 13(9): e403-e408.
18.	Chen TY, Wiltink LM, Nout RA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer, 2015, 14(2): 106-114.
19.	Juul T, Ahlberg M, Biondo S, et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum, 2014, 57(5): 585-591.
20.	Bregendahl S, Emmertsen KJ, Fassov J, et al. Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiother Oncol, 2013, 108(2): 331-336.
21.	Gervaz P, Rotholtz N, Pisano M, et al. Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer. Arch Surg, 2001, 136(2): 192-196.
22.	van Duijvendijk P, Slors JF, Taat CW, et al. Prospective evaluation of anorectal function after total mesorectal excision for rectal carcinoma with or without preoperative radiotherapy. Am J Gastroenterol, 2002, 97(9): 2282-2289.
23.	Emmertsen KJ, Laurberg S, Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg, 2013, 100(10): 1377-1387.
24.	Krol R, Hopman WP, Smeenk RJ, et al. Increased rectal wall stiffness after prostate radiotherapy: relation with fecal urgency. Neurogastroenterol Motil, 2012, 24(4): 339-e166.
25.	Qin Q, Huang B, Cao W, et al. Bowel dysfunction after low anterior resection with neoadjuvant chemoradiotherapy or chemotherapy alone for rectal cancer: a cross-sectional study from China. Dis Colon Rectum, 2017, 60(7): 697-705.
26.	Hupkens BJP, Martens MH, Stoot JH, et al. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection—a matched-controlled study. Dis Colon Rectum, 2017, 60(10): 1032-1040.
27.	Battersby NJ, Juul T, Christensen P, et al. Predicting the risk of bowel-related quality-of-life impairment after restorative resection for rectal cancer: a multicenter cross-sectional study. Dis Colon Rectum, 2016, 59(4): 270-280.
28.	Ozgen Z, Ozden S, Atasoy BM, et al. Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis. Radiat Oncol, 2015, 10: 168.
29.	Pucciarelli S, Del Bianco P, Efficace F, et al. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg, 2011, 253(1): 71-77.
30.	Couwenberg AM, Burbach JPM, van Grevenstein WMU, et al. Effect of neoadjuvant therapy and rectal surgery on health-related quality of life in patients with rectal cancer during the first 2 years after diagnosis. Clin Colorectal Cancer, 2018, 17(3): e499-e512.
31.	Huang M, Lin J, Yu X, et al. Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report. Int J Colorectal Dis, 2016, 31(7): 1349-1357.
32.	Br?ndengen M, Tveit KM, Bruheim K, et al. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase Ⅲ study. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1017-1024.
33.	Kennedy ED, Schmocker S, Victor C, et al. Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? Cancer, 2011, 117(13): 2853-2862.
34.	Kornmann M, Henne-Bruns D, Porzsolt F. Neoadjuvant treatment of rectal carcinoma: assessment of health care services by physicians and lay persons. J Clin Oncol, 2008, 26(30): 4866-4868.
35.	Sun Z, Adam MA, Kim J, et al. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. Colorectal Dis, 2017, 19(12): 1058-1066.
36.	Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol, 2014, 32(6): 513-518.
37.	Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: Final results of the Chinese FOWARC multicenter randomized trial. J Clin Onco, 2018, 36(15_suppl): 3502.
38.	Bossé D, Mercer J, Raissouni S, et al. PROSPECT eligibility and clinical outcomes: results from the Pan-Canadian Rectal Cancer Consortium. Clin Colorectal Cancer, 2016, 15(3): 243-249.
39.	Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol, 2016, 17(2): 174-183.
40.	Habr-Gama A, Gama-Rodrigues J, S?o Juli?o GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys, 2014, 88(4): 822-828.
41.	Breukink SO, Hoff C, Belgers EJ, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst, 2016, 108(12): pii: djw171.
42.	Habr-Gama A, Lynn PB, Jorge JM, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum, 2016, 59(4): 264-269.
43.	Beets GL, Figueiredo NL, Habr-Gama A, et al. A new paradigm for rectal cancer: Organ preservation: Introducing the International Watch & Wait Database (IWWD). Eur J Surg Oncol, 2015, 41(12): 1562-1564.
44.	Hüttner FJ, Tenckhoff S, Jensen K, et al. Meta-analysis of reconstruction techniques after low anterior resection for rectal cancer. Br J Surg, 2015, 102(7): 735-745.
45.	鐘清華, 吳培煌, 秦啟元, 等. 直腸癌術前放療造成手術切緣放射性損傷的病理學研究. 中華外科雜志, 2017, 55(7): 507-514.
46.	秦啟元, 鄺穎儀, 馬騰輝, 等. 近側擴大切除手術治療新輔助放化療后局部進展期直腸癌療效分析. 中華胃腸外科雜志, 2017, 20(11): 1256-1262.
47.	魏波, 衛洪波. 再談直腸癌根治術中Denonvilliers筋膜切除與否. 中華胃腸外科雜志, 2017, 20(6): 640-641.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, Sep 12.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. 王磊, 劉志華, 汪建平. 我國結直腸癌的診療現狀. 中華實驗外科雜志, 2015, 32(4): 677-679.
4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 2004, 351(17): 1731-1740.
5. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol, 2011, 12(6): 575-582.
6. Qin Q, Wang L. Neoadjuvant therapy and subsequent treatment in rectal cancer: balance between oncological and functional outcomes. J Anus Rectum Colon, 2018, 2(2): 47-58.
7. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol, 2005, 23(24): 5644-5650.
8. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years. J Clin Oncol, 2012, 30(16): 1926-1933.
9. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol, 2012, 30(31): 3827-3833.
10. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg, 2006, 93(10): 1215-1223.
11. Ansari N, Solomon MJ, Fisher RJ, et al. Acute adverse events and postoperative complications in a randomized trial of preoperative short-course radiotherapy versus long-course chemoradiotherapy for T3 adenocarcinoma of the rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). Ann Surg, 2017, 265(5): 882-888.
12. Bujko K, Nowacki MP, Kepka L, et al. Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation. Colorectal Dis, 2005, 7(4): 410-416.
13. Ma B, Gao P, Song Y, et al. Short-course radiotherapy in neoadjuvant treatment for rectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer, 2018 Aug 11. pii: S1533-0028(18)30295-0.
14. Kripp M, Wieneke J, Kienle P, et al. Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer-impact on long-term quality of life. Eur J Surg Oncol, 2012, 38(6): 472-477.
15. Sclafani F, Peckitt C, Cunningham D, et al. Short- and long-term quality of life and bowel function in patients with mri-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 expert-c trial. Int J Radiat Oncol Biol Phys, 2015, 93(2): 303-312.
16. Bregendahl S, Emmertsen KJ, Lous J, et al. Bowel dysfunction after low anterior resection with and without neoadjuvant therapy for rectal cancer: a population-based cross-sectional study. Colorectal Dis, 2013, 15(9): 1130-1139.
17. Bryant C L, Lunniss P J, Knowles C H, et al. Anterior resection syndrome. Lancet Oncol, 2012, 13(9): e403-e408.
18. Chen TY, Wiltink LM, Nout RA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer, 2015, 14(2): 106-114.
19. Juul T, Ahlberg M, Biondo S, et al. Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum, 2014, 57(5): 585-591.
20. Bregendahl S, Emmertsen KJ, Fassov J, et al. Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiother Oncol, 2013, 108(2): 331-336.
21. Gervaz P, Rotholtz N, Pisano M, et al. Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer. Arch Surg, 2001, 136(2): 192-196.
22. van Duijvendijk P, Slors JF, Taat CW, et al. Prospective evaluation of anorectal function after total mesorectal excision for rectal carcinoma with or without preoperative radiotherapy. Am J Gastroenterol, 2002, 97(9): 2282-2289.
23. Emmertsen KJ, Laurberg S, Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg, 2013, 100(10): 1377-1387.
24. Krol R, Hopman WP, Smeenk RJ, et al. Increased rectal wall stiffness after prostate radiotherapy: relation with fecal urgency. Neurogastroenterol Motil, 2012, 24(4): 339-e166.
25. Qin Q, Huang B, Cao W, et al. Bowel dysfunction after low anterior resection with neoadjuvant chemoradiotherapy or chemotherapy alone for rectal cancer: a cross-sectional study from China. Dis Colon Rectum, 2017, 60(7): 697-705.
26. Hupkens BJP, Martens MH, Stoot JH, et al. Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection—a matched-controlled study. Dis Colon Rectum, 2017, 60(10): 1032-1040.
27. Battersby NJ, Juul T, Christensen P, et al. Predicting the risk of bowel-related quality-of-life impairment after restorative resection for rectal cancer: a multicenter cross-sectional study. Dis Colon Rectum, 2016, 59(4): 270-280.
28. Ozgen Z, Ozden S, Atasoy BM, et al. Long-term effects of neoadjuvant chemoradiotherapy followed by sphincter-preserving resection on anal sphincter function in relation to quality of life among locally advanced rectal cancer patients: a cross-sectional analysis. Radiat Oncol, 2015, 10: 168.
29. Pucciarelli S, Del Bianco P, Efficace F, et al. Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. Ann Surg, 2011, 253(1): 71-77.
30. Couwenberg AM, Burbach JPM, van Grevenstein WMU, et al. Effect of neoadjuvant therapy and rectal surgery on health-related quality of life in patients with rectal cancer during the first 2 years after diagnosis. Clin Colorectal Cancer, 2018, 17(3): e499-e512.
31. Huang M, Lin J, Yu X, et al. Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report. Int J Colorectal Dis, 2016, 31(7): 1349-1357.
32. Br?ndengen M, Tveit KM, Bruheim K, et al. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase Ⅲ study. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1017-1024.
33. Kennedy ED, Schmocker S, Victor C, et al. Do patients consider preoperative chemoradiation for primary rectal cancer worthwhile? Cancer, 2011, 117(13): 2853-2862.
34. Kornmann M, Henne-Bruns D, Porzsolt F. Neoadjuvant treatment of rectal carcinoma: assessment of health care services by physicians and lay persons. J Clin Oncol, 2008, 26(30): 4866-4868.
35. Sun Z, Adam MA, Kim J, et al. Association between neoadjuvant chemoradiation and survival for patients with locally advanced rectal cancer. Colorectal Dis, 2017, 19(12): 1058-1066.
36. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol, 2014, 32(6): 513-518.
37. Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: Final results of the Chinese FOWARC multicenter randomized trial. J Clin Onco, 2018, 36(15_suppl): 3502.
38. Bossé D, Mercer J, Raissouni S, et al. PROSPECT eligibility and clinical outcomes: results from the Pan-Canadian Rectal Cancer Consortium. Clin Colorectal Cancer, 2016, 15(3): 243-249.
39. Renehan AG, Malcomson L, Emsley R, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol, 2016, 17(2): 174-183.
40. Habr-Gama A, Gama-Rodrigues J, S?o Juli?o GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys, 2014, 88(4): 822-828.
41. Breukink SO, Hoff C, Belgers EJ, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst, 2016, 108(12): pii: djw171.
42. Habr-Gama A, Lynn PB, Jorge JM, et al. Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum, 2016, 59(4): 264-269.
43. Beets GL, Figueiredo NL, Habr-Gama A, et al. A new paradigm for rectal cancer: Organ preservation: Introducing the International Watch & Wait Database (IWWD). Eur J Surg Oncol, 2015, 41(12): 1562-1564.
44. Hüttner FJ, Tenckhoff S, Jensen K, et al. Meta-analysis of reconstruction techniques after low anterior resection for rectal cancer. Br J Surg, 2015, 102(7): 735-745.
45. 鐘清華, 吳培煌, 秦啟元, 等. 直腸癌術前放療造成手術切緣放射性損傷的病理學研究. 中華外科雜志, 2017, 55(7): 507-514.
46. 秦啟元, 鄺穎儀, 馬騰輝, 等. 近側擴大切除手術治療新輔助放化療后局部進展期直腸癌療效分析. 中華胃腸外科雜志, 2017, 20(11): 1256-1262.
47. 魏波, 衛洪波. 再談直腸癌根治術中Denonvilliers筋膜切除與否. 中華胃腸外科雜志, 2017, 20(6): 640-641.

Previous Article
直腸癌新輔助治療后手術方式的選擇
Next Article
局部進展期直腸癌新輔助治療決策：結合 NCCN 和 ESMO 指南的分析

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

直腸癌新輔助治療對患者生活質量的影響

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content